Aniracetam vs Fasoracetam

Cognitive

Cognitive

Research Only

Research Only

Aniracetam is a positive allosteric modulator of AMPA-type ionotropic glutamate receptors. X-ray crystallographic and electrophysiological work on the GluA2 ligand-binding domain demonstrates that aniracetam binds at the dimer interface, on the twofold axis of molecular symmetry, adjacent to the hinge of the clamshell-like ligand-binding core. This binding stabilizes the closed-cleft, glutamate-bound conformation and slows receptor deactivation and desensitization, a mechanism distinct from piracetam's binding site.

Fasoracetam is characterized in the human trial literature and rodent pharmacology as a metabotropic glutamate receptor (mGluR) activator/modulator rather than a classical ionotropic glutamate agent. Rodent studies (Shirayama et al., 1999) demonstrated that it increases acetylcholine release in the cerebral cortex, enhances high-affinity choline uptake in cortex and hippocampus without changing choline acetyltransferase activity, and reverses memory disruption induced by the GABA-B agonist baclofen—suggesting a dual mechanism of facilitating cholinergic neurotransmission and suppressing GABA-B-receptor-mediated responses. No receptor-binding affinity (Ki/EC50) data for specific mGluR subtypes have been located in primary sources.